Yoshihiro Noda

Dr. Yoshihiro Noda

Psychiatry, International University of Health and Welfare, Tokyo, Japan, Tokyo, Japan
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
KSKenji Sanada
Kenji Sanada
SNShinichiro Nakajima
Shinichiro Nakajima
SKShunya Kurokawa
Shunya Kurokawa
ABAlberto Barceló-Soler
Alberto Barceló-Soler
DIDaisuke Ikuse
Daisuke Ikuse
TKTaishiro Kishimoto
Taishiro Kishimoto

12 October 2018 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
SMSho Moriguchi
Sho Moriguchi
ATAkihiro Takamiya
Akihiro Takamiya
Yoshihiro NodaYoshihiro Noda
Yoshihiro Noda
NHNobuyuki Horita
Nobuyuki Horita
MWMasataka Wada
Masataka Wada
SNShinichiro Nakajima
Shinichiro Nakajima
Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of depression, and the glutamatergic system represents a treatment target for depression. To summarize the nature of glutamatergic alterations in patients with depression, we conducted a meta-analysis of proton magnetic resonance (1H-MRS) spectroscopy studies examining levels of glutamate. We used the search terms: depress* AND (MRS OR “magnetic resonance spectroscopy”). The search was performed with MEDLINE, Embase, and PsycINFO. The inclusion criteria were 1H-MRS studies comparing levels of glutamate + glutamine (Glx), glutamate, or glutamine between patients with depression and healthy controls. Standardized mean differences (SMD) were calculated to assess group differences in the levels of glutamatergic neurometabolites. Forty-nine studies met the eligibility criteria, which included 1180 patients and 1066 healthy controls. There were significant decreases in Glx within the medial frontal cortex (SMD = −0.38; 95% CI, −0.69 to −0.07) in patients with depression compared with controls. Subanalyses revealed that there was a significant decrease in Glx in the medial frontal cortex in medicated patients with depression (SMD = −0.50; 95% CI, −0.80 to −0.20), but not in unmedicated patients (SMD = −0.27; 95% CI, −0.76 to 0.21) compared with controls. Overall, decreased levels of glutamatergic metabolites in the medial frontal cortex are linked with the pathophysiology of depression. These findings are in line with the hypothesis that depression may be associated with abnormal glutamatergic neurotransmission.

1 July 2018 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
KOKamiyu Ogyu
Kamiyu Ogyu
KKKaoruhiko Kubo
Kaoruhiko Kubo
Yoshihiro NodaYoshihiro Noda
Yoshihiro Noda
YIYusuke Iwata
Yusuke Iwata
STSakiko Tsugawa
Sakiko Tsugawa
SNShinichiro Nakajima
Shinichiro Nakajima

27 July 2016 in Neuropsychopharmacology
Verified
Journal Article
Closed access
RCRobin F H Cash
Robin F H Cash
Yoshihiro NodaYoshihiro Noda
Yoshihiro Noda
RZReza Zomorrodi
Reza Zomorrodi
NRNatasha Radhu
Natasha Radhu
FFFaranak Farzan
Faranak Farzan
DBDaniel M Blumberger
Daniel M Blumberger

28 September 2021 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
TNTomomi Nakahara
Tomomi Nakahara
STSakiko Tsugawa
Sakiko Tsugawa
Yoshihiro NodaYoshihiro Noda
Yoshihiro Noda
FUFumihiko Ueno
Fumihiko Ueno
SHShiori Honda
Shiori Honda
SNShinichiro Nakajima
Shinichiro Nakajima